½ÃÀ庸°í¼­
»óǰÄÚµå
1562247

À¯·´ÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ¿¹Ãø(-2030³â) : Áö¿ªº° ºÐ¼® - À¯Çüº°, Ä¡·áº°, ¿¬·Éº°, ÃÖÁ¾»ç¿ëÀÚº°

Europe Myopia Treatment Market Forecast to 2030 - Regional Analysis - by Type, Treatment, Age Group, and End User

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 114 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

À¯·´ ±Ù½Ã Ä¡·á ½ÃÀåÀº 2022³â 25¾ï 1,879¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2030³â¿¡´Â 47¾ï 4,613¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 8.2%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

±Ù½Ã Ä¡·á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ À¯·´ ±Ù½Ã Ä¡·á ½ÃÀåÀ» ÁÖµµ

±Ù½Ã Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ±Ù½Ã Ä¡·á ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÃÖ±Ù ½ÃÀå ºÐ¼®¿¡ µû¸£¸é ±Ù½Ã °ü¸® Àü·«¿¡ ´ëÇÑ ÀνÄ, ƯÈ÷ ºÎ¸ð¿Í ¾È°ú Àü¹®°¡µé »çÀÌ¿¡¼­ ±Ù½Ã °ü¸® Àü·«¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ±Ù½Ã ´ëÃ¥ÀÇ ½ÇÇàÀÌ Å©°Ô Áõ°¡Çϰí ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¼¼°è ¾È°ú ÀÇ·áÀÇ ¼±µÎÁÖÀÚÀÎ ÀÌ È¸»ç´Â ±¹³» ÃÖ°íÀÇ °Ë¾ÈÇб³ 3°÷°ú Á¦ÈÞÇØ 2024³âºÎÅÍ ±Ù½Ã È®´ë Ä¡·á¸¦ ½Ã¹üÀûÀ¸·Î Á¦°øÇÒ ¿¹Á¤ÀÔ´Ï´Ù. ÀÎ½Ä °³¼± Ä·ÆäÀÎ, ±³À° ÀÌ´Ï¼ÅÆ¼ºê, ±¤¹üÀ§ÇÑ ¿¬±¸ Á¶»ç·Î °ü¸®µÇÁö ¾Ê´Â ±Ù½ÃÀÇ ÀáÀçÀû ¿µÇâ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ Àû±ØÀûÀÎ ±Ù½Ã °ü¸® Á¢±Ù¹ýÀ¸·ÎÀÇ ÀüȯÀÌ µÎµå·¯Áö°Ô ³ªÅ¸³ª°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ±Ù½Ã Ä¡·á ±â¼ú, Áï ±Ù½Ã ±³Á¤¼ú°ú ¾à¹° ÁßÀç µîÀÇ ±Ù½Ã Ä¡·á ±â¼úÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖÀ¸¸ç, ±× °á°ú Áö³­ 2³â°£ ½ÃÀå ±Ô¸ð°¡ 25% ÀÌ»ó ¼ºÀåÇß½À´Ï´Ù. ±Ù½Ã¸¦ °øÁߺ¸°Ç ¹®Á¦·Î ÀνÄÇÏ°í ±Ù½Ã °ü¸® ¼Ö·ç¼ÇÀÇ ½ÇÇà °¡´É¼ºÀ» ÃËÁøÇϱâ À§ÇÑ Á¾ÇÕÀûÀÎ ³ë·ÂÀº ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí Àû±ØÀûÀÎ ½Ã·Â °ü¸® ¹®È­¸¦ Á¶¼ºÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¸ð¸àÅÒÀº ±Ù½Ã Ä¡·áÀÇ ¹ßÀüÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖÀ¸¸ç, ±Ù½Ã °ü¸® ¹× Ä¡·á Àü·«ÀÇ Àü¸ÁÀ» Çü¼ºÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

À¯·´ÀÇ ±Ù½Ã Ä¡·á ½ÃÀå °³¿ä

À¯·´ ±Ù½Ã Ä¡·á ½ÃÀå¿¡´Â µ¶ÀÏ, ÇÁ¶û½º, ¿µ±¹, ½ºÆäÀÎ, ÀÌÅ»¸®¾Æ ¹× ±âŸ À¯·´¿¬ÇÕ ½ÃÀåÀÌ Æ÷ÇԵ˴ϴÙ. À¯·´Àº ¼¼°è ±Ù½Ã Ä¡·á ½ÃÀå¿¡¼­ Áß¿äÇÑ À§Ä¡¸¦ Â÷ÁöÇϰí ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È °ßÁ¶ÇÑ ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀåÀº ³ëÀÎ Àα¸ÀÇ Áõ°¡, À¯·´ ³» ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡, ÀÌ Áö¿ª ³» Á¦Ç° µµÀÔ Áõ°¡¿¡ ±âÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µ¶ÀÏÀº ³ë·É Àα¸°¡ Å©°Ô Áõ°¡Çϰí ÀÖ¾î ´« °Ç°­º¸Á¶Á¦ äÅÃÀÌ Áõ°¡ÇÒ ¼ö ÀÖ´Â ÁÁÀº ±âȸ·Î, 'World Population Ageing 2017'¿¡ µû¸£¸é 2017³â µ¶ÀÏ Àüü Àα¸ÀÇ ¾à 28%°¡ 60¼¼ ÀÌ»óÀ̸ç, 2050³â±îÁö ¾à 37.6%±îÁö Áõ°¡ÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. Áõ°¡ÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¶ÇÇÑ Æò±Õ ¼ö¸íÀº ¿©¼ºÀº 83¼¼, ³²¼ºÀº 78¼¼°¡ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ Æò±Õ ¼ö¸íÀÇ ¿¬ÀåÀº ´« °Ç°­¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ±Ã±ØÀûÀ¸·Î ¿¹Ãø ±â°£ µ¿¾È µ¶ÀÏ ±Ù½Ã Ä¡·á ½ÃÀåÀ» °ßÀÎÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

À¯·´ ±Ù½Ã Ä¡·á ½ÃÀå ¸ÅÃâ ¹× 2030³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)

À¯·´ ±Ù½Ã Ä¡·á ½ÃÀå ¼¼ºÐÈ­

À¯·´ ±Ù½Ã Ä¡·á ½ÃÀåÀº À¯Çü, Ä¡·á, ¿¬·É´ë, ÃÖÁ¾»ç¿ëÀÚ ¹× ±¹°¡º°·Î ºÐ·ùµË´Ï´Ù.

À¯Çüº°·Î À¯·´ ±Ù½Ã Ä¡·á ½ÃÀåÀº °íµµ ±Ù½Ã, ÅðÇ༺ ±Ù½Ã, ÁøÇ༺ ±Ù½Ã·Î ±¸ºÐµÇ¸ç, 2022³â À¯·´ ±Ù½Ã Ä¡·á ½ÃÀå Á¡À¯À²Àº °íµµ ±Ù½Ã ºÐ¾ß°¡ °¡Àå ÄǽÀ´Ï´Ù.

Ä¡·á Ãø¸é¿¡¼­ À¯·´ ±Ù½Ã Ä¡·á ½ÃÀåÀº Àú¿ë·® ¾ÆÆ®·ÎÇÉ Á¡¾ÈÁ¦, ÄÜÅÃÆ®·»Áî, Ortho-K, ±¼Àý±³Á¤¼ö¼ú·Î ±¸ºÐµË´Ï´Ù. Àú¿ë·® ¾ÆÆ®·ÎÇÉ Á¡¾ÈÁ¦ ºÎ¹®Àº 2022³â À¯·´ ±Ù½Ã Ä¡·á ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¶ÇÇÑ, ±¼Àý ¼ö¼ú ºÎ¹®Àº ¶ó½Ä ¹× PRK·Î ¼¼ºÐÈ­µË´Ï´Ù.

¿¬·É´ëº°·Î À¯·´ ±Ù½Ã Ä¡·á ½ÃÀåÀº ¼ºÀÎ ±Ù½Ã¿Í ¼Ò¾Æ ±Ù½Ã·Î ³ª´¹´Ï´Ù. ¼ºÀÎ ±Ù½Ã ºÎ¹®Àº 2022³â À¯·´ ±Ù½Ã Ä¡·á ½ÃÀå¿¡¼­ ´õ Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚ¿¡ µû¶ó À¯·´ ±Ù½Ã Ä¡·á ½ÃÀåÀº º´¿ø ¹× Ŭ¸®´Ð, Àü¹® Ŭ¸®´Ð, ±¼Àý ±³Á¤ ¼ö¼ú ¼¾ÅÍ·Î ºÐ·ùµÇ¸ç, 2022³â À¯·´ ±Ù½Ã Ä¡·á ½ÃÀå Á¡À¯À²Àº º´¿ø ¹× Ŭ¸®´Ð ºÎ¹®ÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î À¯·´ ±Ù½Ã Ä¡·á ½ÃÀåÀº µ¶ÀÏ, ¿µ±¹, ÀÌÅ»¸®¾Æ, ÇÁ¶û½º, ½ºÆäÀÎ, ±âŸ À¯·´À¸·Î ºÐ·ùµË´Ï´Ù. µ¶ÀÏÀº 2022³â À¯·´ ±Ù½Ã Ä¡·á ½ÃÀå Á¡À¯À²À» µ¶Â÷ÁöÇß½À´Ï´Ù.

Alcon AG, Bausch Health Companies Inc, Carl Zeiss AG, CooperVision Inc, Eyes Vision SL, Haag-Streit AG, Johnson & Johnson Vision Care Inc, Nidek Co Ltd. Ziemer Ophthalmic Systems AG µîÀÌ À¯·´ ±Ù½Ã Ä¡·á ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ÁÖ¿ä ±â¾÷µéÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¹üÀ§
  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç

Á¦4Àå À¯·´ÀÇ ±Ù½Ã Ä¡·á ½ÃÀå »óȲ

  • °³¿ä
  • PEST ºÐ¼®
  • ±â¾÷ Á¡À¯À² ºÐ¼®

Á¦5Àå À¯·´ÀÇ ±Ù½Ã Ä¡·á ½ÃÀå - ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • À¯·´ÀÇ ±Ù½Ã Ä¡·á ½ÃÀå - ÁÖ¿ä ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ±Ù½Ã À¯º´·ü »ó½Â
    • ±Ù½Ã Ä¡·á¿¡ ´ëÇÑ ÀÎ½Ä È®»ê
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¼÷·ÃµÈ Àü¹®°¡ÀÇ ºÎÁ·
  • ½ÃÀå ±âȸ
    • Ÿ°ÙÀ¸·Î ÇÏ´Â ±Ù½Ã¸¦ Ä¡·áÇϱâ À§ÇÑ Ã·´Ü ±â¼ú ÀÌ¿ë °¡´É¼º Áõ°¡
  • ÇâÈÄ µ¿Çâ
    • ±Ù½Ã Ä¡·áÀÇ ÀΰøÁö´É ÀÀ¿ë
  • ¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇâ

Á¦6Àå ±Ù½Ã Ä¡·á ½ÃÀå : À¯·´ ½ÃÀå ºÐ¼®

Á¦7Àå ±Ù½Ã Ä¡·á À¯·´ ½ÃÀå ºÐ¼® : À¯Çüº°

  • °íµµ ±Ù½Ã
  • ÅðÇ༺ ±Ù½Ã
  • ÁøÇ༺ ±Ù½Ã

Á¦8Àå À¯·´ÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ºÐ¼® : Ä¡·áº°

  • Àú¿ë·® ¾ÆÆ®·ÎÇÉ Á¡¾ÈÁ¦
  • ±¼Àý±³Á¤ ¼ö¼ú
  • ÄÜÅÃÆ®·»Áî
  • ¿À¸£¼Ò K

Á¦9Àå À¯·´ÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ºÐ¼® : ¿¬·ÉÃþº°

  • ¼ºÀÎ ±Ù½Ã
  • ¼Ò¾Æ ±Ù½Ã

Á¦10Àå À¯·´ÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø ¹× Ŭ¸®´Ð
  • Àü¹® Ŭ¸®´Ð
  • ±¼Àý±³Á¤ ¼ö¼ú ¼¾ÅÍ

Á¦11Àå À¯·´ÀÇ ±Ù½Ã Ä¡·á ½ÃÀå : ±¹°¡º° ºÐ¼®

  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ±âŸ À¯·´

Á¦12Àå ¾÷°è »óȲ

  • ±Ù½Ã Ä¡·á ½ÃÀåÀÇ ¼ºÀå Àü·«
  • À¯±âÀû ¼ºÀå Àü·«
  • ¹«±âÀû ¼ºÀå Àü·«

Á¦13Àå ±â¾÷ °³¿ä

  • Bausch Health Companies Inc
  • Alcon AG
  • CooperVision Inc
  • Johnson & Johnson Vision Care Inc
  • Ziemer Ophthalmic Systems AG
  • Nidek Co Ltd
  • Eyes Vision SL
  • Haag-Streit AG
  • Carl Zeiss AG

Á¦14Àå ºÎ·Ï

ksm 24.10.10

The Europe myopia treatment market was valued at US$ 2,518.79 million in 2022 and is expected to reach US$ 4,746.13 million by 2030; it is estimated to register a CAGR of 8.2% from 2022 to 2030.

Increased Awareness of Myopia Treatment drives Europe Myopia Treatment Market

The heightened awareness of myopia treatment options drives the substantial growth of the myopia treatment market. A recent market analysis revealed that the increasing awareness of myopia management strategies, particularly among parents and eyecare professionals, has led to a significant upsurge in implementing myopia control measures. The leader in global eye care is teaming up with three of the best optometry schools in the country to provide extended myopia therapy to a pilot group starting in 2024. As awareness campaigns, educational initiatives, and extensive research studies continue to shed light on the potential consequences of unmanaged myopia, there has been a notable shift toward proactive myopia management approaches. This trend has furthered the adoption of myopia treatment technologies, such as orthokeratology and pharmaceutical interventions, resulting in a remarkable increase in the market size, which has grown by over 25% in the last two years. The collective efforts to raise awareness about myopia as a public health concern and to promote the viability of myopia management solutions are propelling market growth and fostering a culture of proactive vision care. This momentum is likely to continue driving advancements in myopia treatment, emphasizing the pivotal role of awareness in shaping the landscape of myopia management and treatment strategies.

Europe Myopia Treatment Market Overview

The Europe myopia treatment market includes the consolidated markets for Germany, France, the UK, Spain, Italy, and the Rest of Europe. Europe occupies a significant position in the global myopia treatment market and is estimated to register a robust growth rate during the forecast period. The market growth in the region is expected due to the increasing geriatric population, rising emphasis on preventive care in Europe, and rising number of product introductions in the region. Germany's extensively increasing geriatric population represents a lucrative opportunity for increased adoption of eye health supplements in the country. As per the "World Population Ageing 2017," in 2017, ~28% of the total population of Germany was aged 60 or more, and it is estimated to rise to nearly 37.6% by the year 2050. It also mentioned that life expectancy is projected to be 83 years for women and 78 years for men. Such higher life expectancy will likely impact eye health, eventually driving the Germany myopia treatment market during the forecast period.

Europe Myopia Treatment Market Revenue and Forecast to 2030 (US$ Million)

Europe Myopia Treatment Market Segmentation

The Europe myopia treatment market is categorized into type, treatment, age group, end user, and country.

Based on type, the Europe myopia treatment market is segmented into high myopia, degenerative myopia, and progressive myopia. The high myopia segment held the largest Europe myopia treatment market share in 2022.

In terms of treatment, the Europe myopia treatment market is segmented into low-dose atropine eye drops, contact lenses, ortho-k, and refractive surgery. The low-dose atropine eye drops segment held the largest Europe myopia treatment market share in 2022. Furthermore, the refractive surgery segment is subcategorized into LASIK and PRK.

By age group, the Europe myopia treatment market is bifurcated into adult myopia and childhood myopia. The adult myopia segment held a larger Europe myopia treatment market share in 2022.

Based on end user, the Europe myopia treatment market is categorized into hospitals and clinics, specialty clinics, and refractive surgery centers. The hospitals and clinics segment held the largest Europe myopia treatment market share in 2022.

Based on country, the Europe myopia treatment market is categorized into Germany, the UK, Italy, France, Spain, and the Rest of Europe. Germany dominated the Europe myopia treatment market share in 2022.

Alcon AG, Bausch Health Companies Inc, Carl Zeiss AG, CooperVision Inc, Eyes Vision SL, Haag-Streit AG, Johnson & Johnson Vision Care Inc, Nidek Co Ltd, and Ziemer Ophthalmic Systems AG are among the leading companies operating in the Europe myopia treatment market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Myopia Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Market Share Analysis, By Companies

5. Europe Myopia Treatment Market - Key Market Dynamics

  • 5.1 Europe Myopia Treatment Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Prevalence of Myopia
    • 5.2.2 Increased Awareness of Myopia Treatment
  • 5.3 Market Restraints
    • 5.3.1 Lack of Skilled Professionals
  • 5.4 Market Opportunities
    • 5.4.1 Rising Availability of Advanced Technologies for Treating The Targeted Myopia
  • 5.5 Future Trends
    • 5.5.1 Application of Artificial Intelligence in Myopia Treatment
  • 5.6 Impact of Drivers and Restraints:

6. Myopia Treatment Market - Europe Market Analysis

7. Europe Myopia Treatment Market Analysis - by Type

  • 7.1 High Myopia
    • 7.1.1 Overview
    • 7.1.2 High Myopia: Europe Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.2 Degenerative Myopia
    • 7.2.1 Overview
    • 7.2.2 Degenerative Myopia: Europe Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Progressive Myopia
    • 7.3.1 Overview
    • 7.3.2 Progressive Myopia: Europe Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Myopia Treatment Market Analysis - by Treatment

  • 8.1 Low-Dose Atropine Eye Drops
    • 8.1.1 Overview
    • 8.1.2 Low-Dose Atropine Eye Drops: Europe Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.2 Refractive Surgery
    • 8.2.1 Overview
    • 8.2.2 Refractive Surgery: Europe Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
    • 8.2.3 LASIK
    • 8.2.4 PRK
  • 8.3 Contact Lenses
    • 8.3.1 Overview
    • 8.3.2 Contact Lenses: Europe Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Ortho-K
    • 8.4.1 Overview
    • 8.4.2 Ortho-K: Europe Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Myopia Treatment Market Analysis - by Age Group

  • 9.1 Adult Myopia
    • 9.1.1 Overview
    • 9.1.2 Adult Myopia: Europe Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.2 Childhood Myopia
    • 9.2.1 Overview
    • 9.2.2 Childhood Myopia: Europe Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Myopia Treatment Market Analysis - by End User

  • 10.1 Hospitals and Clinics
    • 10.1.1 Overview
    • 10.1.2 Hospitals and Clinics: Europe Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.2 Specialty Clinics
    • 10.2.1 Overview
    • 10.2.2 Specialty Clinics: Europe Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.3 Refractive Surgery Centers
    • 10.3.1 Overview
    • 10.3.2 Refractive Surgery Centers: Europe Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)

11. Europe Myopia Treatment Market - Country Analysis

  • 11.1 Europe
    • 11.1.1 Europe: Myopia Treatment Market - Revenue and Forecast Analysis - by Country
      • 11.1.1.1 Europe: Myopia Treatment Market - Revenue and Forecast Analysis - by Country
      • 11.1.1.2 Germany
      • 11.1.1.3 Germany: Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.3.1 Germany: Myopia Treatment Market Breakdown, by Type
        • 11.1.1.3.2 Germany: Myopia Treatment Market Breakdown, by Treatment
        • 11.1.1.3.3 Germany: Myopia Treatment Market Breakdown, by Refractive Surgery
        • 11.1.1.3.4 Germany: Myopia Treatment Market Breakdown, by Age Group
        • 11.1.1.3.5 Germany: Myopia Treatment Market Breakdown, by End User
      • 11.1.1.4 France
      • 11.1.1.5 France: Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.5.1 France: Myopia Treatment Market Breakdown, by Type
        • 11.1.1.5.2 France: Myopia Treatment Market Breakdown, by Treatment
        • 11.1.1.5.3 France: Myopia Treatment Market Breakdown, by Refractive Surgery
        • 11.1.1.5.4 France: Myopia Treatment Market Breakdown, by Age Group
        • 11.1.1.5.5 France: Myopia Treatment Market Breakdown, by End User
      • 11.1.1.6 UK
      • 11.1.1.7 UK: Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.7.1 UK: Myopia Treatment Market Breakdown, by Type
        • 11.1.1.7.2 UK: Myopia Treatment Market Breakdown, by Treatment
        • 11.1.1.7.3 UK: Myopia Treatment Market Breakdown, by Refractive Surgery
        • 11.1.1.7.4 UK: Myopia Treatment Market Breakdown, by Age Group
        • 11.1.1.7.5 UK: Myopia Treatment Market Breakdown, by End User
      • 11.1.1.8 Italy
      • 11.1.1.9 Italy: Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.9.1 Italy: Myopia Treatment Market Breakdown, by Type
        • 11.1.1.9.2 Italy: Myopia Treatment Market Breakdown, by Treatment
        • 11.1.1.9.3 Italy: Myopia Treatment Market Breakdown, by Refractive Surgery
        • 11.1.1.9.4 Italy: Myopia Treatment Market Breakdown, by Age Group
        • 11.1.1.9.5 Italy: Myopia Treatment Market Breakdown, by End User
      • 11.1.1.10 Spain
      • 11.1.1.11 Spain: Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.11.1 Spain: Myopia Treatment Market Breakdown, by Type
        • 11.1.1.11.2 Spain: Myopia Treatment Market Breakdown, by Treatment
        • 11.1.1.11.3 Spain: Myopia Treatment Market Breakdown, by Refractive Surgery
        • 11.1.1.11.4 Spain: Myopia Treatment Market Breakdown, by Age Group
        • 11.1.1.11.5 Spain: Myopia Treatment Market Breakdown, by End User
      • 11.1.1.12 Rest of Europe
      • 11.1.1.13 Rest of Europe: Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.13.1 Rest of Europe: Myopia Treatment Market Breakdown, by Type
        • 11.1.1.13.2 Rest of Europe: Myopia Treatment Market Breakdown, by Treatment
        • 11.1.1.13.3 Rest of Europe: Myopia Treatment Market Breakdown, by Refractive Surgery
        • 11.1.1.13.4 Rest of Europe: Myopia Treatment Market Breakdown, by Age Group
        • 11.1.1.13.5 Rest of Europe: Myopia Treatment Market Breakdown, by End User

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in Myopia Treatment Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Bausch Health Companies Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Alcon AG
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 CooperVision Inc
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Johnson & Johnson Vision Care Inc
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Ziemer Ophthalmic Systems AG
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Nidek Co Ltd
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Eyes Vision SL
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Haag-Streit AG
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Carl Zeiss AG
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦